RxDoctor Payments Data

Thomas Franzon, MD

Clinical Cardiac Electrophysiology · Kalamazoo, MINPI 1740676295

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (52.5%), food and beverage and grants — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Medtronic at 50.4% of the total. Reporting peaked in 2023 at $9,041 and has fallen 59.7% since, to $3,639 in 2025.

$22,694in general payments, 2019–2025

Across 230 payments — averaging $98.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$11K
  • Abbott$6K
  • Boston Scientific$2K
  • Biotronik Inc.$630
  • Cardiva Medical, Inc.$583
  • Biosense Webster, Inc.$408
  • plus $1K from 19 others

What the payments were for

  • Grants$3,12514%
  • Travel & lodging$11,90852%
  • Food & beverage$7,59233%
  • Education$690%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,694 in reported general payments places this provider in the 60th percentile of 105 clinical cardiac electrophysiology providers in Michigan.

See all clinical cardiac electrophysiology providers in Michigan

Medicare billing

Part B allowed, 2024
$99,989
Medicare patients
447
Services billed
986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban168$184,620
XareltoRivaroxaban23$26,101
EntrestoSacubitril/Valsartan12$11,641
Flecainide Acetate82$4,280
Metoprolol Succinate189$3,580
Amiodarone Hcl75$1,498
Diltiazem 24hr Er (Cd)Diltiazem Hcl34$977
Potassium Chloride22$368
Colchicine36$349
SotalolSotalol Hcl11$230
Furosemide26$203
Metoprolol Tartrate34$159
Omeprazole29$149
Cephalexin19$61

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$120$184,620168 claims
Johnson & JohnsonXarelto$13$26,10123 claims
NovartisEntresto$67$11,64112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 105 clinical cardiac electrophysiology providers in Michigan.

Other clinical cardiac electrophysiology in Kalamazoo

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →